학술논문

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC(5)D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma